Evaluation of protocols for the prevention of MTCT in HBV carrier mother.

Evaluation of mother-to-child transmission (MTCT) prophylaxis protocols including methods of administration of HBV immune globulin and timing of vaccination.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180137

Enrollment

Registered

2019-02-19

Start date

2012-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV carrier Viral hepatitis

Interventions

To prevent HBV mother-to-child transmission, HBIG is simultaneously administered both intramuscularly (200 units) and intravenously (500 units) after birth.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The baby from a HBV carrier mother

Exclusion criteria

Exclusion criteria: 1. The baby from a mother who has HBV DNA negative with HBsAb positive. 2. Other treatments are given priority to the baby.

Design outcomes

Primary

Measure	Time frame
The prohibition rates of mother-to-child transmission.	—

Secondary

Measure	Time frame
Alteration of HBsAb titer in baby after treatments.	—

Contacts

Public ContactKoushi Yamaguchi

National Center for Child health and Development

Yamaguchi-k@ncchd.go.jp+81-3-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026